Tree-Based Mining of Real-World Data for Potential Safety Signals Associated with the Use of Dupilumab in the United States (2017-2023)

Dupilumab is a monoclonal antibody authorized for use in the management of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis in the US. Real-world data on the safety of dupilumab are limited.

This poster displays a broad screening assessment of the safety of dupilumab using tree-based scan statistics (TBSS). It was presented at the 2024 ISPE Annual Meeting.